Market-data firm estimates 2020 global drug sales at $987 billion
The annual report from Evaluate Pharma, World Preview 2015, Outlook to 2020, compiles a variety of data on research, drug pipelines, and current and projected sales. By its count, the No. 1 biopharma company in the world both in 2014 and 2020, will be Novartis, with projected sales of $53.3 billion (the company tracks only drug sales, and not other businesses that biopharma firms might be engaged in). Pfizer, the longtime No. 1 firm until recently, is projected to remain No. 2, even though 2020 sales will be essentially flat from 2014’s $4.6 billion. In fact, the top 20 firms collectively will show CAGR of 3%, while the projection for global sales will rise with a CAGR of 5%, to $987 billion. Companies not among the top 20 will grow at a CAGR of 8%.
Some other tidbits from the Evaluate Pharma report:
The full report is available for download at www.evaluatepharma.com.
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.